NOVATO, Calif., Sept. 4 BioMarin PharmaceuticalInc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D.,Chief Medical Officer of BioMarin, will present a company update at the BearStearns 20th Annual Healthcare Conference in New York City on Tuesday,September 11, 2007 at 3:00 p.m. ET.
Interested parties may access a live audio webcast of the presentation viathe investor section of the BioMarin website, http://www.BMRN.com. A replayof the presentation will be archived on the site for at least one weekfollowing the presentation.
BioMarin develops and commercializes innovative biopharmaceuticals forserious diseases and medical conditions. The company's product portfolio iscomprised of two approved products and multiple clinical and preclinicalproduct candidates. Approved products include Naglazyme(R) (galsulfase) formucopolysaccharidosis VI (MPS VI), a product wholly developed andcommercialized by BioMarin, and Aldurazyme(R) (laronidase) formucopolysaccharidosis I (MPS I), a product which BioMarin developed through a50/50 joint venture with Genzyme Corporation. Investigational productcandidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 productcandidate for the treatment of phenylketonuria (PKU), and 6R-BH4 forcardiovascular indications, which is currently in Phase 2 clinical developmentfor the treatment of peripheral arterial disease and sickle cell disease.Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-6594
SOURCE BioMarin Pharmaceutical Inc.